Quotient Sciences Header

Quotient Sciences Header

X

Find Neurology Drugs in Phase I Clinical Development in AUSTRIA

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Affiris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson\\'s Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Affiris"},{"company":"Affiris","sponsor":"AC Immune","pharmaFlowCategory":"D","amount":"$100.8 million","upfrontCash":"$5.0 million","newsHeadline":"AC Immune Acquires AFFiRiS\u2019 Specific Active Immunotherapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Affiris"}]

Affiris

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AC Immune Acquires AFFiRiS’ Specific Active Immunotherapy

Details:

AC Immune is acquiring AFFiRiS’ anti-alpha-synuclein programs (PD01) targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.

Lead Product(s): PD01

Therapeutic Area: Neurology Product Name: PD01

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: AC Immune

Deal Size: $100.8 million Upfront Cash: $5.0 million

Deal Type: Acquisition July 27, 2021

ASK
US

Upload
your Pipeline Activity

Affiris

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson's Disease Patients

Details:

In its written response, the FDA addressed AFFiRiS' questions and provided guidance on the design of the planned phase 2 trial.

Lead Product(s): PD01

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY